Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Announces Management Structure

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2020 | 07:24am EDT

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas' ) today announced the following Executive Comittee Standing Members effective from April 1, 2020.

Executive Committee: an organization that discusses and decides on important matters of management across Astellas. It is chaired by the Representative Director, President and CEO, and comprises Top Management and the General Counsel as standing members. Extended members include the heads of research, development, pharmaceutical technology, and commercial divisions, who will participate in any necessary discussions at the request of the chairman.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contact:

Tel: +81-3-3244-3201

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTELLAS PHARMA INC.
05/21ASTELLAS PHARMA INC. : - Notice Regarding Continuation of the Performance-linked..
AQ
05/21ASTELLAS PHARMA : European Medicines Agency Accepts Astellas Marketing Authoriza..
AQ
05/14ASTELLAS PHARMA : Immunomic Therapeutics, Inc. - Maryland's Immunomic Therapeuti..
AQ
05/11ASTELLAS PHARMA INC. : annual earnings release
04/29ASTELLAS PHARMA : Efforts against the Spread of the Coronavirus Disease
AQ
04/27ASTELLAS PHARMA : and Harvard Establish Strategic Research Alliance
PU
04/27ASTELLAS PHARMA INC. : - Change of Directors and Organizational Change
AQ
04/21ASTELLAS PHARMA : Announces Acquisition of Nanna
AQ
04/10ASTELLAS PHARMA : Announces Acceptance of XOSPATA for Regulatory Review in China..
AQ
04/06ASTELLAS PHARMA : and BANDAI NAMCO Entertainment Enter into Agreement to Co-Deve..
AQ
More news
Financials (JPY)
Sales 2020 1 275 B
EBIT 2020 257 B
Net income 2020 204 B
Finance 2020 458 B
Yield 2020 2,25%
P/E ratio 2020 16,1x
P/E ratio 2021 15,8x
EV / Sales2020 2,29x
EV / Sales2021 2,28x
Capitalization 3 379 B
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 2 133,33 JPY
Last Close Price 1 818,00 JPY
Spread / Highest target 54,0%
Spread / Average Target 17,3%
Spread / Lowest Target -17,5%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-2.78%29 719
JOHNSON & JOHNSON-0.67%380 857
ROCHE HOLDING AG9.63%302 928
PFIZER, INC.-4.52%208 251
MERCK & CO., INC.-14.73%195 012
NOVARTIS AG-10.47%187 475